fiegyd Office: ".iJJollsuquJaU.

$_‘LthJ-. me N0. 53. 31'I‘J'Jy 'J\'0. 5&3

zydus |('1L1i-iiRC11tlJiilqu43:). NJlalsiliczfijegg‘1fl;ilffiCadila

.L'. E", - - J

deuicate3/)?3 G HiMJW‘3’E-IEWJWE‘JJ

Healthcare Limited

November 21, 2019

Listing Department Code: 532 321

BSE LIMITED

PJ Towers, Dalal Street, Fort,

Mumbai—400 001

Listing Department Code: CADILAHC

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai—400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated November 21, 2019 titled “Zydus receives

final approvals from the USFDA for Isosorbide Dinitrate Tablets and Desonide Cream."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the

investors’ at large.

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

WW. ’

DHAVAL N. SONICOMPANY SECRETARY

Encl.: As above

HMWWHMHMHWWHUSTAMWEEHVSBWWHWfléfiflfifiiflMZO-lineaf www.zyduscadila.com CIN : L24230GJ1995PL0025878

Zydusdedicated['

to Z 3 P1935 I‘Lelease P1955; Release

Press Release

Pless Release Press Release

Zydus receives final approvals from the USFDA for

Isosorbide Dinitrate Tablets and Desonide Cream

Ahmedabad. 21 November 2019

Zydus Cadila has received the final approval from the USFDA to market lsosorbide Dinitrate

Tablets USP (US RLD — Isordil Tablet) in the strengths ofS mg, 10 mg, 20 mg, 30 mg and 40

mg. The drug is used to prevent attacks of chest pain (angina). lt dilates (widens) blood vessels,

making it easier for blood to flow through them and easier for the heart to pump. It will be

manufactured at the group’s formulations manufacturing facility at Baddi.

The group also received the final approval for Desonide Cream (US RLD — Desonide Cream),0.05%. The drug is a mild corticosteroid, used to treat a variety of skin conditions (e.g., eczema,

dermatitis, allergies, rash) to reduce swelling, itching and redness that can occur in these types

of conditions. It will be manufactured at the group’s Topical manufacturing facility at

Ahmedabad.

The group now has 278 approvals and has so far filed over 330 ANDAs since the

commencement of the filing process in FY 2003—04.

About Zydus CadilaZydus Cadila is an innovative, global pharmaceutical company that discovers, develops,

manufactures and markets a broad range of healthcare therapies. The group employs over

24,000 people worldwide and is dedicated to creating healthier communities globally. Zydus

aspires to be a research-based pharmaceutical company by 2020.

*1”:

For further information please contact: Cadila Healthcare LimltedThe Corporate Communications Department Hegd. Office :‘Zydus Corporate Park'. Scheme No. 63. Survey No. 536. Khoraj (Gandhinagar),

NLVaishnodevi Circle, S. G. Highway. Ahmedabad 3B2 431. India.Phone :+91—079-71300000, +91-079-4BD40000 mmzyduscadilaeomCIN : L242SOGJ1995PLCO2SBTB